Leflunomide-Hydroxychloroquine Combo Shows Potential for Sjögren’s Patients in Pilot Trial
A combination of leflunomide and hydroxychloroquine significantly reduced disease activity, increased salivary flow, and improved patient-perceived health in patients with primary Sjögren’s syndrome, a pilot trial showed. Findings of the trial were revealed at the recent American College of Rheumatology 2018 Meeting, in Chicago. Timothy Radstake, MD, PhD, from the …